




ENHANCING PATIENT CARE

for CAR T-Cell Therapy in NHL:

Comprehensive Solutions for Your Community



Summary of FDA-Approved CAR T-Cell Therapies for NHL



Brand Name	Targeted Hematologic Malignancies	Pivotal Trial(s)
Tisagenlecleucel (tisa-cel) (Kymriah)	Adults with R/R LBCL after 2 or more lines of systemic therapy Adults with R/R FL after 2 or more lines of systemic therapy	JULIET ELARA
Axicabtagene ciloleucel (axi-cel) (Yescarta)	Adults with R/R LBCL after 2 or more lines of systemic therapy Adults with R/R FL after 2 or more lines of systemic therapy* Adults with LBCL that are refractory to first-line chemoimmunotherapy or that relapses ≤ 12 months	ZUMA-1 ZUMA-5 ZUMA-7
Brexucabtagene autoleucel (brexu-cel) (Tecartus)	Adult patients with R/R MCL*	ZUMA-2
Lisocabtagene maraleucel (liso-cel) (Breyanzi)	Adults with R/R LBCL after 2 or more lines of systemic therapy Adults with LBCL that are refractory to first-line chemoimmunotherapy or that relapses ≤ 12 months and not eligible for HSCT due to age or comorbidities Adult patients with R/R CLL/SLL who have been treated with at least 2 lines of therapy, including a BCL-2 inhibitor and a BTK inhibitor* Adults with R/R FL after 2 or more lines of systemic therapy* Adults with R/R MCL after at least 2 lines of systemic therapy, including a BTKinhibitor	TRANSCEND NHL-001 TRANSFORM TRANSCEND CLL-004 TRANSCEND FL TRANSCEND NHL-001

Efficacy and Safety of Available CAR T-cell Therapy in R/R NHL

Disease	Product	Efficacy ORR, EFS/PFS	CRS All (severe), time to onset & resolution	Neurotoxicity All (severe), time to onset & resolution
Diffuse large B-cell lymphoma (DLBCL)	Axicabtagene ciloleucel	83%, 8.3 months	92% (6%), 3d, 7d	60% (21%), 7d, 9d
	Lisocabtagene maraleucel	73%, 10.1 months	49% (1%), 5d, 4d	12% (4%), 11d, 6d
	Tisagenlecleucel	46.3%, 3.0 months	61% (5%), 4d, 5d	10% (2%), 5d, 9d
Mantle cell lymphoma (MCL)	Brexucabtagene autoleucel	93%, 25.8 months	91% (15%), 2d, 11d	63% (31%), 7d, 12d
	Lisocabtagene maraleucel	85.3%, 15.3 months	54% (3.2%), 5d	31% (10%), 8d, 7d
Follicular lymphoma (FL)	Axicabtagene ciloleucel	89%, 39.6 months	82% (7%), 4d, 6d	59% (19%), 7d, 14d
	Tisagenlecleucel	86%, 57.4% @ 24 months	49% (0%), 4d, 4d	37% (1%), 9d, 2d
	Lisocabtagene maraleucel	95.7%, 91.3% @ 12 months	52.2% (0%), 6d, 3d	17.4% (4%), 8.5d, 2.5d
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)	Lisocabtagene maraleucel	95.7%, not reached	83% (9%)	46% (20%)

*Indication is approved under accelerated approval.

BCL-2, B-cell lymphoma 2; BCMA, B-cell maturation antigen; BTK, Bruton tyrosine kinase; CD19, Cluster of Differentiation 19; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; FL, follicular lymphoma; LBCL, large B-cell lymphoma; MCL, mantle cell lymphoma; NHL, non-Hodgkin lymphoma; R/R, relapsed/refractory. U.S. Food & Drug Administration. Cellular & Gene Therapy Products.; U.S. Prescribing Information. CRS, cytokine release syndrome; d, days; DOR, duration of response; EFS, event-free survival; NR, not reached; ORR, overall response rate; PFS, progression-free survival. Locke FL, et al. N Engl J Med. 2022;386:640-654; Bishop MR, et al. N Engl J Med. 2022;386:629-639; Kamdar M, et al. Lancet. 2022;399(10343):2294-2308; Wang M, et al. N Engl J Med. 2020;382:1331-1342; Wang M, et al. J Clin Oncol. 2022;41(3):555-567; Jacobson CA, et al. Lancet Oncol. 2022;23(1):91-103; Neelapu SS, et al. Blood. 2021;138(suppl 1):93. Fowler NH, et al. Nat Med. 2022;28(2):325-332; Dreyling M, et al. Blood. 2022;140(suppl 1):1459-1463; Lee DW, et al. Blood 2014;124:188-195.; Morschhauser F, et al. Blood 2023; 142 (Supplement 1): 602.